Condition: Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma · Sponsor: Grifols Biologicals, LLC
The main goal of this study is to show that people with certain immune problems (from Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma) get fewer serious infections when they receive Gamunex C through an IV once every 4 weeks, along with their usual medical care, for one year. All participants will receive Gamunex-C 500 mg/kg once every 4 weeks (total 13 doses) starting Day 1 (Week 1) through Week 48 (end of Treatment Phase).
This description comes directly from the study's public registry record.
Judith Wessels-Kranz · +49 6103 801-6395, · judith.wesselskranz@external.grifols.com,
Marina Acosta Enslen · +1 (919) 813 9725 · marina.acostaenslen@grifols.com
Always discuss trial participation with your own doctor first.
| Study Site 102 | St. Petersburg, Florida, United States | Not Yet Recruiting |
| Study Site 101 | Fort Wayne, Indiana, United States | Recruiting |
| Study Site 105 | Westbrook, Maine, United States | Not Yet Recruiting |
| Study Site 104 | Columbus, Ohio, United States | Not Yet Recruiting |
| Study Site 103 | Tacoma, Washington, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07582432